Finally, characterizing the signals that influence the differentiation from CD8 TEM to CD8 TEX could offer novel therapeutic targets to stimulate the differentiation of anti-tumoural CD8 TEX cells towards a more activated phenotype, particularly in those patients displaying primary resistance to atezo/bev. This evidence concerns the gene CD8A and neoplasm.